Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M709Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M35.8EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)18.7Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.210-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.3PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M5,846,503ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with BBH

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BBH is held by these investors:



BBH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481160.76view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94605.55view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1770205.88view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.368688.24view
Bebek, IvanDirector 2017-01-16Buy8,990$3.383436.09view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4129051.22view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91328.23view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271806.22view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3897.95view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1579580view

Quarterly/Annual Reports about BBH:

    News about BBH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Biotech ETFs Powered by Q4 Earnings Feb 10 2017
    What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
    Dow moves within 50 points of 20,000 after Trump news conference Jan 11 2017
    Biotech ETFs fall as Trump says more bidding needed on drugs Jan 11 2017
    Why These Collaborations Are Important to Incyte Jan 09 2017
    What’s the Outlook for Gilead Sciences? Jan 03 2017
    Gilead Sciences’ Valuation Compared to Its Peers Dec 30 2016
    Biotech plays for the new year Dec 28 2016
    2017 Playbook: Biotech & pharma Dec 28 2016
    VanEck Announces Year-End Distributions for Vaneck Vectors Equity ETFs Dec 16 2016
    How to play health care stocks under Trump: Pro Dec 14 2016
    Can Trump keep promise to reduce drug prices? Dec 14 2016
    Why Valbenazine Studies Seem Promising Dec 01 2016
    Epclusa: Gilead Sciences’s Pan-Genotype Product Dec 01 2016
    Trump Effect Elevated These Sector ETFs to Rank #1 Nov 30 2016
    Understanding Allergan’s 3Q16 Revenue Stream Nov 29 2016
    VanEck Announces Preliminary Year-End Distribution Estimates for VanEck Vectors Equity ETFs Nov 22 2016
    5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016
    Biotech ETFs Slumping on Q3 Results Nov 08 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)